Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100 million (USD 13.7 million) in a Series B financing round. The funding was led by SDIC Unity Capital, with participation from BioTrack Capital, a returning investor. The proceeds will be used to support new product research and development, clinical studies, regulatory filings, and chip iterations, among other initiatives.
Company Background and Core Products
Founded in 2018, SeeNeuro Medical is known for its core product, a spinal nerve stimulator (SCS). The device effectively treats intractable pain by implanting electrodes into the patient’s spine, stimulating spinal nerves with pulse current, and blocking pain signals from being transmitted to the brain through the spinal cord. The company also offers a peripheral nerve stimulator (PNS), an in-house developed temporary and short-term peripheral nervous regulatory system designed to relieve acute and chronic pain.
Future Development Plans
Looking ahead, SeeNeuro Medical plans to develop solutions for various totally implanted peripheral nerve stimulators, autonomic nerve stimulators, and more. The company aims to expand its product portfolio and enhance its technological capabilities to address a broader range of pain management needs.
Recent Financing Activity
In the past year, SeeNeuro Medical has closed three financing rounds, each exceeding RMB 100 million (USD 13.7 million). This consistent fundraising activity underscores the company’s strong market position and commitment to advancing its innovative neural regulation devices.-Fineline Info & Tech
